Clinical trial · no report yet · Phase 1/Phase 2
LuCAB
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
- NCT05340374 ↗
- Active, not recruiting
- Peter MacCallum Cancer Centre, Australia
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 12 | |
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer; mCRPC
- Interventions
- Cabazitaxel; 177Lu-PSMA-617
- Arms
- Treatment Arm · Experimental
- Enrollment
- 35
- Primary outcomes
- Number of participants with Dose Limiting Toxicities (DLTs)
- Maximum Tolerated dose (MTD)
- Recommended Phase 2 Dose (RP2D)
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Start
- Jul 14, 2022
- Primary completion
- Jun 20, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05340374 · updated Apr 6, 2025
Publications
linked from the registry- Kostos L, Buteau JP, Kong G, Tran B, Haskali MB, Fahey M, Crumbaker M, Emmett L, Hofman MS, Azad AA. Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2025 Apr 1;66(4):572-578. doi: 10.2967/jnumed.124.269252. PubMed 39978808